A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

Фаза 2 Завершено NCT01387555

Заболевание	Hepatocellular Carcinoma, Liver Cancer, HCC
Фаза	Фаза 2
Спонсор	Jennerex Biotherapeutics
Статус	Завершено
Участники	129 участн.
Вмешательство	JX-594 recombinant vaccina GM-CSF, Best Supportive Care
Дата начала	8.10.2011
Дата завершения	1.10.2013
Публикация результатов	8.07.2026

Кратко

This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.

Survival

From randomization until death from any cause, assessed up to 21 months. · months

JX-594 + Best Supportive Care	4.2 months
Best Supportive Care	4.4 months

p-value	0.426
Hazard Ratio (HR)	1.19 (95% CI 0.78–1.80)

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.

English 한국어 日本語中文 Русский